HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After US FDA Finds ‘Particularly Concerning’ GMP Problems, Homeopathic Firm Continues OTC Sales

Executive Summary

A warning letter submitted by FDA Office of Regulatory Affairs’ Division of Pharmaceutical Quality Operations I in New Jersey notes that Homeocare Laboratories indicated to agency officials that it no longer is manufacturing OTC drugs.

You may also be interested in...



US Homeopathic Firm’s Failure To Test Supplies, Lax Approach On Recalls Lead To Warning

Although Washington Homeopathic informed FDA it recalled homeopathics manufactured by a supplier on import alert and would recall “high risk” tinctures, it would allow its customers to decide whether to return other products also identified as potentially adulterated.

FDA Adds Homeopathic Enforcement Details, Subtracts Compliance Policy Guide

Revised draft guidance identifies types of homeopathics posing "higher risks to public health." FDA withdraws 1988 compliance policy guide that allows homeopathic to be available even though they are not subject to pre-market approval or other review process agency imposes on all other drugs.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel